{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:32:20Z","timestamp":1773297140666,"version":"3.50.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","license":[{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Norman Bethune Medical Research Foundation","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>Platinum-resistant ovarian cancer is characterized by its poor prognosis and limited treatment options. Angiogenesis plays a fundamental role in the development of drug-resistance in ovarian cancer. Anlotinib, a novel oral multi-targeted tyrosine kinase inhibitor which targets a board spectrum of angiogenesis-associated growth factor receptors, has shown promising anti-tumor efficacy in clinical trials. Herein, we report a case of ovarian cancer treated with anlotinib plus etoposide after secondary cytoreductive surgery.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 45-year-old female with primary platinum-resistant ovarian cancer who progressed rapidly after the first cytoreductive surgery, the second cytoreductive surgery, and several lines of treatment. The patient refused to receive intravenous chemotherapy any more.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Primary platinum-resistant ovarian cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The oral combination treatment of anlotinib (12\u200amg, qd) and etoposide (100\u200amg, qd) were delivered.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Finally, the patient was responsive to the orally treatment of anlotinib combined with etoposide. The patient has been alive with no evidence of disease progression for 18 weeks.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Our case suggests that oral treatment of anlotinib combined with etoposide which is acceptable and convenient, may be an additional option for the management of platinum-resistant ovarian cancer.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000020053","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T15:57:00Z","timestamp":1589903820000},"page":"e20053","source":"Crossref","is-referenced-by-count":8,"title":["Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer"],"prefix":"10.1097","volume":"99","author":[{"given":"Li","family":"Sun","sequence":"first","affiliation":[{"name":"Departments of Gynecological Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing"},{"name":"Departments of Gynecological Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital l & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Yang","sequence":"additional","affiliation":[{"name":"Departments of Gynecological Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital l & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Departments of Gynecological Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital l & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Li","sequence":"additional","affiliation":[{"name":"Departments of Gynecological Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital l & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingying","family":"Wu","sequence":"additional","affiliation":[{"name":"Departments of Gynecological Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzi","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Medical Department, 3D Medicines Inc, Shanghai, People's Republic of China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shangli","family":"Cai","sequence":"additional","affiliation":[{"name":"The Medical Department, 3D Medicines Inc, Shanghai, People's Republic of China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,5,15]]},"reference":[{"key":"R1-20240521","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R2-20240521","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"351","author":"Cannistra","year":"2004","journal-title":"N Engl J Med"},{"key":"R3-20240521","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ygyno.2014.05.029","article-title":"Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: a retrospective analysis","volume":"134","author":"Petrillo","year":"2014","journal-title":"Gynecol Oncol"},{"key":"R4-20240521","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3802\/jgo.2010.21.2.75","article-title":"Maximal cytoreductive effort in epithelial ovarian cancer surgery","volume":"21","author":"Shih","year":"2010","journal-title":"J Gynecol Oncol"},{"issue":"(Suppl 1)","key":"R5-20240521","doi-asserted-by":"crossref","first-page":"i33","DOI":"10.1093\/annonc\/mdw093","article-title":"Anti-angiogenic agents in ovarian cancer: past, present, and future","volume":"27","author":"Monk","year":"2016","journal-title":"Ann Oncol"},{"key":"R6-20240521","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40265-018-0939-x","article-title":"Anlotinib: first global approval","volume":"78","author":"Syed","year":"2018","journal-title":"Drugs"},{"key":"R7-20240521","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","article-title":"Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRbeta and FGFR1","volume":"654","author":"Lin","year":"2018","journal-title":"Gene"},{"key":"R8-20240521","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","article-title":"Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial","volume":"4","author":"Han","year":"2018","journal-title":"JAMA Oncol"},{"key":"R9-20240521","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jnci.2018.10.003","article-title":"Combined cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as a treatment for recurrent epithelial ovarian cancer-National Cancer Institute experience","volume":"30","author":"Fahim","year":"2018","journal-title":"J Egypt Natl Cancer Inst"},{"key":"R10-20240521","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.gore.2018.11.004","article-title":"Successful treatment of platinum refractory ovarian clear cell carcinoma with secondary cytoreductive surgery and implantable transponder placement to facilitate targeted volumetric arc radiation therapy","volume":"27","author":"Fehniger","year":"2019","journal-title":"Gynecol Oncol Rep"},{"key":"R11-20240521","first-page":"8","article-title":"Cytoreductive surgery followed by HIPEC repetition for secondary ovarian cancer recurrence","author":"Cianci","year":"2018","journal-title":"Updates Surg"},{"key":"R12-20240521","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole\u2013genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"key":"R13-20240521","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.bbagen.2018.11.005","article-title":"Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer\u2014a mini review","volume":"1863","author":"Binju","year":"2019","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"R14-20240521","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ygyno.2015.07.008","article-title":"State of the science: emerging therapeutic strategies for targeting angiogenesis in ovarian cancer","volume":"138","author":"Graybill","year":"2015","journal-title":"Gynecol Oncol"},{"key":"R15-20240521","doi-asserted-by":"crossref","first-page":"97851","DOI":"10.18632\/oncotarget.18415","article-title":"Increased PDGFR-beta and VEGFR-2 protein levels are associated with resistance to platinum-based chemotherapy and adverse outcome of ovarian cancer patients","volume":"8","author":"Avril","year":"2017","journal-title":"Oncotarget"},{"key":"R16-20240521","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ygyno.2013.10.027","article-title":"Platelet-derived growth factor receptor alpha (PDGFRalpha) targeting and relevant biomarkers in ovarian carcinoma","volume":"132","author":"Matsuo","year":"2014","journal-title":"Gynecol Oncol"},{"key":"R17-20240521","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1186\/1471-2407-14-696","article-title":"Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer","volume":"14","author":"Sallinen","year":"2014","journal-title":"BMC Cancer"},{"key":"R18-20240521","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"key":"R19-20240521","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1186\/s12885-018-4505-4","article-title":"An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023","volume":"18","author":"Shoji","year":"2018","journal-title":"BMC Cancer"},{"key":"R20-20240521","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1470-2045(15)70115-4","article-title":"Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial","volume":"16","author":"Pignata","year":"2015","journal-title":"Lancet Oncol"},{"key":"R21-20240521","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(15)00366-6","article-title":"Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"17","author":"du Bois","year":"2016","journal-title":"Lancet Oncol"},{"key":"R22-20240521","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0140-6736(15)01167-8","article-title":"Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"387","author":"Ledermann","year":"2016","journal-title":"Lancet"},{"key":"R23-20240521","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","article-title":"Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development","volume":"11","author":"Shen","year":"2018","journal-title":"J Hematol Oncol"},{"key":"R24-20240521","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1111\/cas.13536","article-title":"Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor","volume":"109","author":"Xie","year":"2018","journal-title":"Cancer Sci"},{"key":"R25-20240521","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1016\/j.bbrc.2018.08.098","article-title":"Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway","volume":"503","author":"He","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"R26-20240521","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/aps.2017.199","article-title":"Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species","volume":"39","author":"Zhong","year":"2018","journal-title":"Acta Pharm Sin"},{"issue":"(15_suppl)","key":"R27-20240521","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1200\/JCO.2016.34.15_suppl.4565","article-title":"Anlotinib versus sunitinib as first line treatment for metastatic renal cell carcinoma (mRCC): Preliminary results from a randomized phase II clinical trial","volume":"34","author":"Ai-Ping Zhou","year":"2016","journal-title":"J Clin Oncol"},{"key":"R28-20240521","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1089\/thy.2018.0022","article-title":"Anlotinib for the treatment of patients with locally advanced or metastatic medullary thyroid cancer","volume":"28","author":"Sun","year":"2018","journal-title":"Thyroid"},{"key":"R29-20240521","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1158\/1078-0432.CCR-17-3766","article-title":"Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma","volume":"24","author":"Chi","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"(15_suppl)","key":"R30-20240521","article-title":"Anlotinib in metastatic renal cell carcinoma (mRCC) with a previous anti-VEGFR TKI: preliminary results from a multicenter, phase II trial","volume":"34","author":"Ai-Ping Zhou","year":"2016","journal-title":"J Clin Oncol"},{"key":"R31-20240521","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.1998.16.2.405","article-title":"Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study","volume":"16","author":"Rose PG1","year":"1998","journal-title":"J Clin Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020053","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T20:08:52Z","timestamp":1716322132000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020053"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2020,5,15]]},"references-count":31,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000020053","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,15]]}}}